Date published: 2026-7-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

PIPK I α CRISPR Activation Plasmid (h): sc-403490-ACT

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • PIPK I α CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
  • PIPK I α CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
  • The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by PIPK I α CRISPR Activation Plasmid (h) and PIPK I α CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PIP5K1A transcriptional start site. One or both designs may be available
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PIPK I α Antibody (D-12): sc-377021
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    PIPK I α CRISPR Activation Plasmid (h)

    sc-403490-ACT
    20 µg
    $397.00

    PIP5K1A encodes phosphatidylinositol-4-phosphate 5-kinase type I alpha (PIPK I α), a key lipid kinase that generates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) at the plasma membrane and endomembranes. PI(4,5)P2 serves as a precursor for second messengers in phosphoinositide signaling and directly regulates actin cytoskeleton remodeling, clathrin-mediated endocytosis, membrane trafficking, and focal adhesion dynamics. Through control of PI(4,5)P2 availability, PIPK I α influences signaling nodes including PLC/PKC and PI3K–AKT pathways and supports spatial organization of receptor-driven signaling. Dysregulated phosphoinositide metabolism and altered PIP5K1A activity have been associated with aberrant cell migration, invasive phenotypes, and oncogenic signaling contexts, making it relevant for mechanistic studies of proliferation and motility programs.

    PIPK I α CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PIP5K1A expression without altering the underlying DNA sequence.

    PIPK I α CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PIP5K1A locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

    Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PIP5K1A transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous PIPK I α expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PIP5K1A locus and enabling the study of PIPK I α-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of PIPK I α pathway restoration in tumor cells with silenced or reduced PIP5K1A expression.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.